中成药作为2型糖尿病补充替代疗法的范围综述
本范围综述基于PRISMA-SCr框架,从三个药物目录提取25种用于2型糖尿病的中成药,并系统检索8个数据库至2023年6月22日,最终纳入449篇全文分析。纳入研究涉及20种中成药,其中约四分之一单用中成药,其余均与口服降糖药联用,最常联用双胍类,空腹血糖是最常报告疗效指标。
要点
- 共25种中成药用于2型糖尿病,但仅20种有相关研究证据。
- 空腹血糖是疗效评价中最常报告的结果指标。
核心结论
- 目前有25种中成药可用于2型糖尿病患者,但相关证据量因品种而异。
- 未来研究需规范中成药与常规药物的联合使用,并选择合适的结果指标。
研究设计与样本
- 遵循PRISMA-SCr框架的范围综述,基于PICOS原则提出问题并从三个药物目录提取中成药。
- 系统检索8个数据库自建库至2023年6月22日的文献,最终纳入449篇全文分析。
主要发现
- 从三个药物目录共提取25种中成药,黄芪在成分中出现频率最高(19次)。
- 449篇全文分析涉及20种中成药,其余5种无相关报告。
- 约四分之一(25.39%,114/449)的研究使用中成药单药治疗,其余均与口服降糖药联用。
- 联用方案中双胍类最常见(50.14%,168/335)。
- 空腹血糖是最常报告的疗效评价指标(82.41%,370/449)。
临床怎么用
- 临床选用中成药治疗2型糖尿病时,应知晓并非所有目录内品种均有研究证据支持。
- 中成药多与口服降糖药(尤其是双胍类)联用,需关注联合用药的规范性与安全性。
- 疗效评价可参考空腹血糖等常用指标,但需结合其他结局全面评估。
局限性
- 原始摘要未明确报告纳入研究的偏倚风险或证据质量评价。
- 原始摘要未报告检索语言限制、发表偏倚等范围综述常见局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This scoping review aims to document Chinese Patent Medicines (CPMs) for Type 2 Diabetes Mellitus, explore whether CPMs can improve patients' health outcomes, and set priorities in addressing research gaps in this area. METHODS: Following the framework of PRISMA-SCr, we proposed the research questions based on PICOS principle, and searched the CPMs for T2DM from three drug lists, followed by a systematic search of the literature in eight databases from their inception to June 22, 2023. Then, we developed the eligibility criteria and systematically reviewed the relevant studies, retained the studies about CPMs for T2DM, extracted the related data, and identified the differences across studies in structured charts. RESULTS: A total of 25 types of CPMs were extracted from the three drug lists. Radix astragali appeared most frequently (19 times) among the herbal medicinal ingredients of CPMs. A total of 449 articles were included in the full-paper analysis ultimately, all of which were about 20 types of CPMs, and there were no related reports on the remaining five CPMs. Except about a quarter (25.39 %, 114/449) using CPMs alone, the remaining studies all involved the combination with oral hypoglycemics for T2DM. Biguanides are the most common drugs used in combination with CPMs (50.14 %, 168/335). Fasting plasma glucose (FPG) is the most frequently reported outcomes in efficacy evaluation (82.41 %, 370/449). CONCLUSION: There are a total of 25 types of CPMs currently available for T2DM patients. However, the volume of related evidence on these CPMs varies. It is necessary to standardize the combined use of CPMs and conventional medicine and select appropriate outcomes in future studies.
引用
- Zheng HZ, Chang TY, Peng B, et al. Chinese patent medicine as a complementary and alternative therapy for type 2 diabetes mellitus: A scoping review. Complement Ther Med. 2024. PMID: 38184284. doi:10.1016/j.ctim.2024.103014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。